



For media/analyst interviews, contact:

Susan Fitzpatrick
DatelineMedia Communications
Office: 02 9006 1614
Cell: 0400246010
EMAIL: susan@datelinemedia.com

FOR IMMEDIATE RELEASE:

NOVOTECH RECOGNIZED IN DELOITTE TECHNOLOGY FAST 500 ASIA PACIFIC 2006 PROGRAM

Sydney, Australia, December 12, 2006 — Novotech, the largest independent Australian owned contract research organization (CRO) and the only Australian CRO with offices in the USA, announced today that it is a winner in the ***Deloitte Fast 500 Asia Pacific 2006 Program***.

The Program run by the leading global consultancy, is supported by the Deloitte Technology Fast 50 initiatives, which rank high growth technology companies [including life sciences companies] by location or specifically defined geographic area, and is sponsored by Deloitte's Technology, Media & Telecommunications (TMT) global industry group.

Novotech, which now employs more than 80 staff in Australia, New Zealand and the USA, also announced recently that it had experienced record growth this year with deals worth more than \$12 million.

Novotech CEO Alek Safarian said inclusion in the Fast 500 again confirmed the company's international standing for managed growth in both Australia and the US, and for embracing the latest in technology and processes that are essential for conducting high-quality global clinical trials, and regulatory consulting.

Novotech recently opened an office in New Jersey on the USA East Coast, which compliments the services offered by the San Diego office on the West Coast, and those in Australia and New Zealand, giving it unmatched presence and geographic coverage amongst other Australian CROs.

The USA operations make it uniquely positioned to offer trials across the two countries, providing the benefits of Australia's highly regarded cost-effective clinical trial capabilities, and at the same time take advantage of access to the much larger US market for rapid patient enrolment - a service that has to date only been available via large global CROs at higher overhead costs.

"Novotech is the ideal partner for Australian and New Zealand companies expanding their clinical development program offshore, and requiring clinical and regulatory affairs services of a CRO in the all important USA market," said Safarian.

About Novotech

Headquartered in Sydney, Novotech is focused on the Australian and New Zealand markets but has worldwide reach through its USA operations on the East and West Coast, as well as strategic alliances in Europe and Asia.

As the largest independent CRO in Australia, Novotech has firmly established itself as the CRO of choice for many US and European biotechnology companies conducting clinical trials in Australia and New Zealand. Novotech's USA operations now make it uniquely positioned to offer trials across the two regions, providing the benefits of Australia's highly regarded cost-effective clinical trial capabilities, and at the same time take advantage of access to the much larger US market for rapid patient enrolment -a service that has to date only been available via large global CROs at higher overhead costs.

www.novotech-cro.com

Deloitte Technology Fast 500 Asia Pacific

The Deloitte Technology Fast 500 Asia Pacific program recognizes technology companies that have achieved the fastest rates of annual revenue growth in Asia Pacific during the past three years. It includes those companies based in Australia, China, Hong Kong SAR, India, Indonesia, Japan, Macau SAR, Malaysia, Philippines, New Zealand, Singapore, South Korea, Taiwan, Thailand and Vietnam. The program is supported by the Deloitte Technology Fast 50 initiatives, which rank high growth technology companies by location or specifically defined geographic area and is sponsored by Deloitte's Technology, Media & Telecommunications (TMT) global industry group.